Amphetamine withdrawal is a real, clinically recognized syndrome that begins within hours of the last dose and unfolds over days to weeks. Unlike alcohol or benzodiazepine withdrawal, it is not typically life-threatening, but it can be profoundly uncomfortable and psychologically destabilizing. The hallmark experience is a “crash” of fatigue, low mood, and intense craving, followed by a longer stretch of subtler symptoms that can persist for a month or more. Despite decades of research, no medication has been convincingly shown to treat it, which makes understanding what to expect all the more important.
What Happens in the Brain
Amphetamines work by flooding the brain with dopamine and, to a lesser extent, norepinephrine and serotonin. With repeated use, the brain adapts by dialing down its own dopamine production and sensitivity. When the drug is suddenly removed, the brain is left in a dopamine-depleted state. Animal research has shown that chronic amphetamine administration can reduce forebrain dopamine levels by over 40%, and that even a month after stopping, dopamine levels can remain roughly 18% below normal.1PubMed. The effect of chronic administration and withdrawal of amphetamine on cerebral dopamine receptor sensitivity This shortfall in the brain’s main reward and motivation chemical is what drives most withdrawal symptoms, from the deep fatigue to the inability to feel pleasure.
The psychological state that follows stimulant withdrawal has been described as bearing a remarkable similarity to major depressive disorder.2Trends in Pharmacological Sciences. Psychostimulant withdrawal as a model of depression This is not a coincidence or a loose analogy. The same neurotransmitter systems disrupted in clinical depression are the ones left depleted after chronic amphetamine use. The difference is that the withdrawal-related depression is triggered by a specific event and, for most people, gradually resolves as the brain recalibrates.
The Two-Phase Timeline
Research on people withdrawing from methamphetamine (the most-studied amphetamine in withdrawal research) has mapped out a fairly consistent pattern with two distinct phases. The acute phase begins within 24 hours of the last dose, peaks quickly, and then declines in a roughly straight line over about 7 to 10 days. This is followed by a subacute phase lasting at least another two weeks, during which most symptoms stay at low, relatively stable levels.3PubMed. The nature, time course and severity of methamphetamine withdrawal
Some clinicians further divide the post-acute period into an early protracted phase (roughly weeks two through four) and a late protracted phase (beyond four weeks).4PubMed Central. Clinical management of psychostimulant withdrawal: review of the evidence The late protracted phase is the least well-characterized, but people in recovery commonly report lingering low mood, difficulty concentrating, and intermittent cravings that stretch well beyond the first month. The exact duration varies widely depending on how much was used, how long it was used, and individual biology.
Acute Phase Symptoms
The first few days are the most intense. The acute phase is dominated by what researchers call a “reversed vegetative syndrome,” a cluster of symptoms that are essentially the opposite of what the drug produces. Where amphetamines suppress appetite and sleep while boosting energy, withdrawal brings excessive sleeping, increased appetite, and crushing fatigue.5PubMed. Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment Many people describe sleeping 12 to 18 hours a day during the first few days. Alongside these vegetative symptoms, depression, anxiety, and drug craving are all prominent, though the depression-related symptoms and the physical exhaustion tend to dominate over anxiety and craving during this initial crash.3PubMed. The nature, time course and severity of methamphetamine withdrawal
Physically, you might notice a slower heart rate. During active use, amphetamines drive heart rate and blood pressure up. When the drug is removed, a rebound slowing of the heart can occur. This is generally not dangerous in otherwise healthy individuals, but it can feel unsettling, especially combined with the already heavy fatigue.
Anhedonia and the Longer Psychological Tail
Of all the psychological symptoms, anhedonia, the inability to experience pleasure, may be the most clinically significant. Animal studies have shown that amphetamine withdrawal produces an immediate and persistent drop in motivated behavior. Unlike nicotine withdrawal, which also involves mood disruption, the motivational deficit after amphetamine withdrawal appears uniquely deep and long-lasting.6PubMed Central. Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats
Population-level data from American adults confirms this pattern in humans. Lifetime anhedonia is strongly associated with stimulant use and with progression from casual use to dependence, and this relationship holds even after accounting for other psychiatric conditions and substance use. The link between anhedonia and stimulants is distinct from and stronger than the link between general depressed mood and stimulant use, suggesting that the pleasure-system disruption is not just “feeling sad” but something more specific to the brain’s reward circuitry.7PubMed Central. Anhedonia associated with stimulant use and dependence in a population-based sample of American adults
This matters for recovery because anhedonia makes it harder to find the motivation to do the things that support sobriety, such as exercising, socializing, attending treatment, and building new routines. If nothing feels rewarding, the brain defaults to seeking the one thing it remembers feeling good: the drug. Understanding that this flat, colorless emotional state is a predictable and temporary consequence of withdrawal, not a permanent condition, can help people push through.
Sleep Disruption During and After Withdrawal
Sleep problems during amphetamine withdrawal are nearly universal, but they shift in character over time. During the acute crash, most people sleep far more than usual. This hypersomnia is partly the body catching up after prolonged wakefulness, but it also reflects changes in sleep architecture. Amphetamines suppress REM sleep during active use, and when the drug is removed, the brain compensates with a surge of REM activity, a phenomenon known as REM sleep rebound.8PubMed. REM sleep rebound during withdrawal from chronic amphetamine administration is blocked by chloramphenicol This can mean vivid, often disturbing dreams during the first week or so of abstinence.
Once the acute phase passes, the sleep picture often reverses. People in remission from methamphetamine dependence show significantly reduced sleep efficiency, with total sleep time averaging only about five and a half hours despite spending nearly seven hours in bed. REM sleep takes longer than normal to onset, and the lighter stages of sleep are overrepresented.9PubMed Central. Polysomnographic survey of sleep architecture in patients with methamphetamine dependence during remission In other words, even after the hypersomnia resolves, sleep quality may remain poor for months. This is worth knowing because poor sleep feeds directly into low mood, impaired concentration, and increased craving, creating a cycle that can undermine recovery.
Appetite, Weight Gain, and Metabolic Rebound
Weight gain after stopping amphetamines is common enough that many people cite it as a barrier to quitting, especially those who began using the drugs partly for appetite suppression. Research in animal models has confirmed that a history of chronic amphetamine exposure leads to significantly greater food intake and weight gain after cessation compared to controls. Interestingly, the increased eating appears to involve regular food rather than highly palatable “comfort food,” suggesting this is a genuine metabolic and motivational shift rather than simply emotional eating.10PubMed Central. Food consumption and weight gain after cessation of chronic amphetamine administration
The mechanism may be related to the same reward-system changes driving anhedonia. With the brain’s reward circuitry sensitized by chronic drug exposure, food, particularly calorie-dense food, becomes a more compelling stimulus in the drug’s absence. For practical purposes, this means that some weight gain during early recovery is normal and expected. Trying to aggressively restrict calories during withdrawal is likely counterproductive, as it adds another source of discomfort and deprivation to an already difficult period. A more realistic approach is accepting moderate weight fluctuation in the short term while focusing on regular, balanced meals.
Craving as a Predictor of Relapse
Craving during amphetamine withdrawal is not just an unpleasant feeling; it is one of the strongest predictors of whether someone will use again. In prospective research, craving scores that preceded methamphetamine use were about 2.7 times higher than scores that preceded a week of abstinence, and the risk of using in the following week was roughly 2.5 times greater when craving was in the upper half of the scale.11PubMed. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis The predictive power of craving is strongest in the week immediately following the craving report and fades the further out you look.12Substance Abuse: Research and Treatment. How Long Does Craving Predict Use of Methamphetamine? Assessment of Use One to Seven Weeks after the Assessment of Craving
More recent research has identified distinct craving trajectories among people in treatment. Those who fall into a high-craving trajectory are overwhelmingly likely to continue using, with about 88% maintaining a consistently high frequency of use during the trial period. By contrast, those in the low-craving group showed rapidly decreasing use and much better outcomes across the board, including lower dropout rates.13PubMed Central. Trajectories of craving in the course of pharmacotherapy trials for methamphetamine use disorder The clinical takeaway is clear: managing craving is not peripheral to treatment; it is arguably the central challenge. Any strategy that reduces craving intensity, whether behavioral, environmental, or pharmacological, directly improves the odds of staying abstinent.
Why No Medication Has Become Standard
This is one of the more frustrating aspects of amphetamine withdrawal for both patients and clinicians. Unlike opioid withdrawal, where medications like buprenorphine can dramatically reduce symptoms, there is no established pharmacotherapy for amphetamine withdrawal. The evidence base is thin, and the trials that do exist are small and of low quality.
A Cochrane systematic review found that only four randomized controlled trials, involving just 125 participants total, met inclusion criteria. Of the medications tested, amineptine (an antidepressant that was later withdrawn from the market for safety reasons) showed some promise in reducing dropout rates and improving overall clinical presentation, but it did not directly reduce withdrawal symptoms or craving compared to placebo.14PubMed Central. Treatment for amphetamine withdrawal Evidence for mirtazapine, another antidepressant sometimes tried in this setting, was mixed: one study suggested it might help with anxiety and hyperarousal, while a later study found no benefit over placebo.
A more recent systematic review and meta-analysis of nine trials reached a similarly discouraging conclusion. Amineptine showed some benefits, but since the drug is no longer available, the finding is essentially academic. No other medication improved any outcome compared to placebo. The review rated the quality of the evidence as low to very low and called for better-powered trials.15PubMed Central. Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials A broader review of pharmacotherapy for amphetamine dependence overall has found somewhat more encouraging signals for stimulant agonist approaches (using lower-risk stimulants like dexamphetamine or methylphenidate as a kind of substitution therapy) and for naltrexone, but these are studied primarily for reducing ongoing use rather than treating the withdrawal period specifically.16SpringerLink / CNS Drugs. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Some emerging approaches show early promise. Repetitive transcranial magnetic stimulation, a non-invasive brain stimulation technique, and certain medications like bupropion and naltrexone have been noted as having potential across different withdrawal phases.4PubMed Central. Clinical management of psychostimulant withdrawal: review of the evidence But “potential” is doing a lot of heavy lifting in that sentence. The honest state of the science is that clinicians are still largely managing amphetamine withdrawal with supportive care, not targeted pharmacotherapy.
What Supportive Care Actually Looks Like
Given the lack of proven medications, managing amphetamine withdrawal is primarily about creating conditions that let the brain heal while keeping the person safe and as comfortable as possible. In practice, this involves several components:
- Safe environment: For heavy users, the first few days are best spent in a supervised setting, whether that is an inpatient facility or a home environment with a reliable support person. The risk is not primarily medical but behavioral: deep depression and impaired judgment can create safety concerns, and the intensity of craving during the acute phase makes relapse likely without environmental barriers.
- Sleep hygiene: Letting the body sleep as much as it wants during the initial crash, then gradually establishing a regular sleep schedule. Given the persistent sleep architecture changes described above, good sleep practices (consistent bedtime, dark room, no screens before bed) become more important than they might seem.
- Nutrition: Regular, balanced meals from the start. The appetite surge is the body’s way of restoring energy reserves depleted by the drug. Adequate protein and micronutrient intake supports neurotransmitter rebuilding.
- Physical activity: Once the acute exhaustion lifts, moderate exercise is one of the most reliably helpful interventions. It boosts dopamine and endorphin levels naturally and improves sleep quality, addressing two of the core withdrawal problems at once.
- Psychological support: Cognitive behavioral therapy, contingency management (where people earn tangible rewards for staying abstinent), and peer support groups are the treatments with the best evidence for stimulant use disorders overall. These are especially important during the subacute and protracted phases, when the acute misery has faded but anhedonia and craving linger.
Symptom-specific medications may still be prescribed off-label. A short course of sleep medication for insomnia, a low-dose antidepressant if depression is severe, or a benzodiazepine for acute anxiety are all reasonable clinical decisions. The point is that these are treating individual symptoms, not the withdrawal syndrome itself, and they should be used cautiously given the population’s vulnerability to developing new dependencies.
Prescription Amphetamines and Withdrawal
Much of the research discussed so far involves methamphetamine, which tends to be used at much higher doses and in more chaotic patterns than prescription amphetamines like Adderall or Vyvanse. This raises a reasonable question: does withdrawal from therapeutic-dose prescription amphetamines look the same?
The short answer is that the same basic syndrome applies, but the severity is generally much milder. Someone who has taken a prescribed dose of 20 to 30 milligrams of amphetamine salts daily for ADHD and then stops will likely experience fatigue, increased appetite, low mood, and difficulty concentrating, but the profound depression, hypersomnia lasting days, and intense craving seen in heavy methamphetamine users are far less common at therapeutic doses. The withdrawal from prescription amphetamines also tends to resolve faster, often within a week or two. Tapering the dose gradually rather than stopping abruptly further reduces symptoms, and most prescribers will recommend a taper for anyone who has been on the medication for more than a few weeks.
That said, prescription amphetamine withdrawal is still under-recognized. People who stop ADHD medication often attribute the resulting fatigue and concentration problems entirely to their underlying ADHD returning, not realizing that withdrawal is compounding the picture. Being aware that some of the initial difficulty after stopping is temporary and drug-related, rather than purely a resurgence of the condition being treated, helps set more accurate expectations.
Individual Variation and Risk Factors
Not everyone withdraws the same way. Several factors shape the experience:
- Duration and dose: Longer use and higher doses mean more pronounced neuroadaptation and more severe withdrawal. Someone who has used for months will generally have a harder time than someone who used for weeks.
- Route of administration: Smoking or injecting delivers the drug to the brain faster and at higher concentrations than swallowing a pill, producing steeper neuroadaptation and typically more intense withdrawal.
- Co-occurring mental health conditions: Pre-existing depression or anxiety disorders can make the mood symptoms of withdrawal significantly worse and harder to distinguish from the underlying condition.
- Sex differences: Research suggests that biological sex influences responses to drugs of abuse and the brain changes that follow exposure, though the clinical implications for withdrawal management are still being worked out.17PubMed Central. Sex differences, gender and addiction
- Polysubstance use: Concurrent use of alcohol, cannabis, benzodiazepines, or opioids creates overlapping withdrawal syndromes that complicate both the clinical picture and treatment planning.
The Stress Response During Withdrawal
One underappreciated aspect of amphetamine withdrawal is its effect on how the body handles stress. During active use, amphetamines alter the hypothalamic-pituitary-adrenal axis, the system responsible for the stress hormone cortisol (corticosterone in rodents). Research has found that while baseline stress hormone levels in the blood may not look dramatically different during withdrawal, the way these hormones reach and affect the brain can change. Specifically, corticosterone levels in the hippocampus, a brain region critical for mood and memory, may be altered during withdrawal even when blood levels appear normal.18PubMed Central. Amphetamine withdrawal differentially affects hippocampal and peripheral corticosterone levels in response to stress
What this means practically is that people in amphetamine withdrawal may be more reactive to stress than a simple blood test would suggest. Minor frustrations and everyday hassles can feel overwhelming, not because the person is weak-willed but because the brain’s stress-buffering systems are temporarily compromised. Planning for this, by reducing unnecessary stressors during the first few weeks of withdrawal and having concrete coping strategies in place, is one of the most useful things someone can do to protect their recovery.